WO2023101381A1

WO2023101381A1 - Vaccine platform for producing foot and mouth disease virus-like particles

Info

Publication number: WO2023101381A1
Application number: PCT/KR2022/019148
Authority: WO
Inventors: 김봉윤
Original assignee: 주식회사 왓슨알앤디
Priority date: 2021-11-30
Filing date: 2022-11-30
Publication date: 2023-06-08
Also published as: KR102513632B1; KR20230081996A

Abstract

The present invention relates to a polynucleotide in which the 3C, 3D cleavage site, VP4, VP2, VP3, and VP1 base sequences of foot and mouse disease virus (FMDV) are sequentially connected, a recombinant vector carrying same, a transformant transformed with the recombinant vector, a method for producing foot and mouth disease virus-like particles using the transformant, and a vaccine composition using a food and mouth disease virus-like particle protein that assembles by itself using the polynucleotide. When a vaccine is prepared using the FMDV VLP of the present invention as an antigen, the period of antibody production in mice is short, the survival rate against foot and mouth disease virus challenge is high, and the neutralizing antibody titer is high. In addition, it was observed that antibody production started within about 2 weeks in pigs as well as mice and the PI value was more than 50% even after 6 weeks, so that the vaccine can be applied as a vaccine platform for producing foot and mouth disease virus-like particles.

Description

Vaccine platform for producing foot-and-mouth disease virus-like particles

The present invention relates to a vaccine platform for producing foot-and-mouth disease virus like particles.

Foot and mouth disease virus (FMDV) is an acute infectious disease that is very serious in ungulates, especially cattle and pigs. It causes severe economic losses in the livestock industry with significant impact on the livestock industry through rapid propagation through the air, low fertility and low milk production. This disease is currently classified and designated as a disease to be managed by the World Organization for Animal Health (OIE) as the first livestock infectious disease under the Infectious Disease Prevention Act, and is a disease that must be reported to the World Health Organization when it occurs.

Foot and Mouth Disease Virus (FMDV) is a single-stranded bipolar RNA virus with seven serotypes including O, A, Asia1, C, South African Territories (SAT) 1, SAT 2, and SAT3. This has been confirmed, and mainly Serotype O continues to occur worldwide. In addition, Serotypes Asia1 and A, including Serotype O, are occurring intermittently in East Asian regions such as China and North Korea. Foot-and-mouth disease viruses are not serologically neutralized between viruses of different serotypes, and show genetic or antigenic differences so large that cross-protection by vaccines is not possible.

Looking at the FMDV genome and capsid structure of FIG. 1, the foot-and-mouth disease virus has an exposed capsid, and the capsid has an icosahedral structure.

The P1 region of the foot-and-mouth disease virus polyprotein encodes structural proteins, and the P2 and P3 regions encode non-structural proteins. The structural protein precursor P1 is cleaved by viral protease 2A, and the P1 precursor is processed into capsid proteins VPO, VP3 and VP1. 3C is a viral protease responsible for processing P1 precursors into capsid proteins. VPO, VP1 and VP3 spontaneously assemble an empty capsid and viral RNA is packaged inside the capsid after assembly. The association of empty capsid with genomic RNA leads to conformational shift, internalization of RNA, autocatalytic cleavage of VPO into VP2 and VP4, and maturation into stable virions.

On the other hand, foot-and-mouth disease vaccines are inactivated vaccines are used worldwide, and most of them have been improved in terms of effectiveness by vaccination using oil adjuvant (Double Oil Emulsion, DOE or Single Oil Emulsion, SOE), but antibody production Delayed period, low antibody titer, short antibody persistence, and low immunogenicity in pigs are pointed out as disadvantages.

Traditional vaccines include two types: inactivated vaccines and attenuated vaccines. However, due to unsafe factors such as pathogenic reversion of the virus, incomplete inactivation of the virus, and escape of the live virus from the vaccine processing plant, outbreaks of foot-and-mouth disease in some regions have been reported to be related to the live virus remaining in the inactivated vaccine. However, there are problems with the safety of inactivated vaccines.

In addition, since the attenuated vaccine is also a live virus, the animal retains the virus during the vaccination process, and the attenuated foot-and-mouth disease virus strain is highly likely to recover pathogenicity during the long-term survival in the body of a highly susceptible animal. For this reason, attenuated vaccines are being eliminated, but inactivated vaccines are still widely used in many foot-and-mouth disease outbreak countries and regions, including Korea.

Due to the continuous mutation of the foot-and-mouth disease virus and the emergence of new viruses, the limited ability of traditional inactivated vaccines to protect, the development of vaccines against newly occurring mutant viruses is urgently needed.

The inventors of the present invention inserted two copies of a polynucleotide capable of generating and expressing foot-and-mouth disease virus-like particles (FMDV VLP) by self-assembly into multiple cloning sites (MCS) 1 and MCS 2 of two different vectors and recombined the Vectors were prepared, and the two recombinant vectors were transformed into Escherichia coli, and the copy number was increased by more than 4 times compared to the previous one, confirming that the amount of FMDV VLP antigen contained in the vaccine was high.

In addition, when the vaccine was prepared using the FMDV VLP prepared as described above as an antigen, it was confirmed that the period of antibody production in mice was short, the survival rate was excellent against foot-and-mouth disease virus challenge, and the neutralizing antibody titer was high. In addition, antibody production began in pigs as well as mice in about 2 weeks, and it was confirmed that the PI value was over 50% even after 6 weeks, confirming that it could be applied as a vaccine platform for producing foot-and-mouth disease virus-like particles, and the present invention has been completed.

In order to achieve the above object, an object of the present invention is a polynucleotide in which the N-terminal region of VP4 is substituted with the 3C, 3D cleavage site of foot-and-mouth disease virus (FMDV), the nucleotide sequences of VP4, VP2, VP3, and VP1 are sequentially linked. is to provide

Another object of the present invention is to provide a recombinant vector comprising the polynucleotide.

Another object of the present invention is to provide a transformant transformed with the recombinant vector.

Another object of the present invention is to prepare a transformant by introducing the recombinant vector into a host cell; and culturing the transformant to induce expression of foot-and-mouth disease virus-like particles from the polynucleotide.

Another object of the present invention is a foot-and-mouth disease virus vaccine composition comprising, as an active ingredient, a foot-and-mouth disease virus-like particle protein self-assembled using the polynucleotide, a protein extract of the transformant, or a recombinant protein isolated from the transformant. is to provide

Another object of the present invention is to prevent or prevent foot-and-mouth disease virus, which contains, as an active ingredient, the foot-and-mouth disease virus-like particle protein self-assembled using the polynucleotide, the protein extract of the transformant, or the recombinant protein isolated from the transformant. It is to provide a feed composition for improvement.

Another object of the present invention is to prevent or prevent foot-and-mouth disease virus, which contains, as an active ingredient, the foot-and-mouth disease virus-like particle protein self-assembled using the polynucleotide, the protein extract of the transformant, or the recombinant protein isolated from the transformant. It is to provide a composition for adding feed for improvement.

Another object of the present invention is to provide a method for preventing or treating foot-and-mouth disease virus, comprising administering the vaccine composition, feed composition, or feed additive composition to a non-human mammal.

In the present invention, two types of recombinant vectors are transformed into Escherichia coli, and the copy number is increased by more than 4 times compared to the conventional method, so that the amount of FMDV VLP antigen contained in the vaccine is high.

When a vaccine is prepared using the FMDV VLP prepared as described above as an antigen, the period of antibody production in mice is short, the survival rate against foot-and-mouth disease virus challenge is high, and the neutralizing antibody titer is high. In addition, antibody production started at about 2 weeks in pigs as well as mice, and it was confirmed that the PI value was more than 50% even after 6 weeks, so it can be applied as a vaccine platform for producing foot-and-mouth disease virus-like particles.

Figure 1 shows the FMDV genome and capsid structure.

Figure 2 shows a platform for preparing FMDV VLPs of the present invention.

Figure 3 shows a phylogenetic diagram of foot-and-mouth disease virus.

4 (a, b) shows A-type FMDV A22-Iraq, A-Bangladesh (A-Ban), A-Malaysia97 (A-May97), A-Gimpo (A-GP), A-Pocheon (A-PC ), and A-Yeoncheon (A-YC) A comparison of the amino acid sequences encoded by the polynucleotides used for VLP production (amino acids 2-214: 3C, amino acids 215-218: at the N-terminal region of VP4 Substituted 3D cleavage site, amino acids 219-299: VP4, amino acids 300-517: VP2, amino acids 518-737: VP3, amino acids 738-948: VP1, 3C to 127th bold P: 3C mutation site, VP2 93rd C in bold: VP2 transition position).

5 (a, b, c) shows O-type FMDVs O-PanAsia2 (O-PA2), O1manisa, O-Taiwan97 (O-Twn97), O-Campos, O-Boeun (O-BE), O-Jincheon (O-JC), O-Anseong (O-AS) and O-Gimje (O-GJ) amino acid sequences encoded by polynucleotides used for VLP preparation (2-214th amino acids: 3C, 215 -218th amino acid: 3D cleavage site substituted at the N-terminus of VP4, 219-299th amino acid: VP4, 300-517th amino acid: VP2, 518-737th amino acid: VP3, 738-948th amino acid: VP1, 127th bold P in 3C: 3C transition location, 93rd C bold in VP2: VP2 transition location).

Figure 6 compares the amino acid sequences encoded by the polynucleotides used to prepare Asia1-type Asia1-Shamir and Asia1-Mongol VLPs (amino acids 2-214: 3C, amino acids 215-218: N-terminal of VP4 3D cleavage site substituted at site, amino acids 219-299: VP4, amino acids 300-517: VP2, amino acids 518-736: VP3, amino acids 737-945: VP1, 127th from 3C in bold P: 3C mutation site , 93rd C in VP2 in bold: VP2 transition position).

Figure 7 shows a schematic diagram of the pET-duet vector for cloning foot-and-mouth disease virus-like particles ((FMDV VLP).

Figure 8 shows a schematic diagram of the pACY-duet vector for cloning foot-and-mouth disease virus-like particles ((FMDV VLP).

9 is designed to insert two copies (COPY) into a vector while the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV A22-Iraq in which the N-terminal region of VP4 is substituted with 3C and 3D cleavage sites of FMDV are located in order. It shows the recombinant vector of Global strain A-type FMDV A22-Iraq VLP containing the gene of SEQ ID NO: 5.

10 is a 3C, 3D cleavage site of FMDV, in which the N-terminal region of VP4 is substituted, and the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV A-Bangladesh (A-Ban) are located in order, and two copies (COPY ) shows a recombinant vector of Global strain A-type FMDV A-Bangladesh (A-Ban) VLP containing the gene of SEQ ID NO: 7 designed to be inserted.

11 shows the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV A-Malaysia97 (A-May97) in which the N-terminal region of VP4 is substituted with the 3C and 3D cleavage sites of FMDV, and the nucleotide sequences of VP4, VP2, VP3, and VP1 are located in order, and two copies (COPY ) shows a recombinant vector of Global strain A-type FMDV A-Malaysia97 (A-May97) VLP containing the gene of SEQ ID NO: 9 designed to be inserted.

12 shows the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV A-Gimpo (A-GP) in which the N-terminal region of VP4 is substituted with 3C and 3D cleavage sites of FMDV, and two copies (COPY ) shows a Korea strain A-type FMDV A-Gimpo (A-GP) VLP recombinant vector containing the gene of SEQ ID NO: 11 designed to be inserted.

13 shows the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV A-Pocheon (A-PC) in which the N-terminal region of VP4 is substituted with 3C and 3D cleavage sites of FMDV, and two copies (COPY ) shows a Korea strain A-type FMDV A-Pocheon (A-PC) VLP recombinant vector containing the gene of SEQ ID NO: 13 designed to be inserted.

14 shows the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV A-Yeoncheon (A-YC) in which the N-terminal region of VP4 is substituted with 3C and 3D cleavage sites of FMDV, and two copies (COPY ) shows a recombinant vector of Korea strain A-type FMDV A-Yeoncheon (A-YC) VLP containing the gene of SEQ ID NO: 15 designed to be inserted.

15 shows the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV O-PanAsia2 (O-PA2) in which the N-terminal region of VP4 is substituted with the 3C and 3D cleavage sites of FMDV, and the nucleotide sequences of VP4, VP2, VP3, and VP1 are located in order, and two copies (COPY ) shows a recombinant vector of Global strain O-type FMDV O-PanAsia2 (O-PA2) VLP containing the gene of SEQ ID NO: 17 designed to be inserted.

16 is a sequence number designed to insert two copies (COPY) into a vector while the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV O1manisa in which the N-terminal region of VP4 is substituted with the 3C and 3D cleavage sites of FMDV are located in order. It shows the recombinant vector of Global strain O-type FMDV O1manisa VLP containing 19 genes.

17 shows the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV O-Taiwan97 (O-Twn97) in which the N-terminal region of VP4 was substituted with the 3C and 3D cleavage sites of FMDV, and the nucleotide sequences of VP4, VP2, VP3, and VP1 were placed in order and two copies (COPY ) is shown as a global strain O-type FMDV O-Taiwan97 (O-Twn97) VLP recombinant vector containing the gene of SEQ ID NO: 21 designed to be inserted.

18 is designed to insert two copies (COPY) into a vector while the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV O-Campos in which the N-terminal region of VP4 is substituted with 3C and 3D cleavage sites of FMDV are located in order. It shows the recombinant vector of Global strain O-type FMDV O-Campos VLP containing the gene of SEQ ID NO: 23.

19 shows the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV O-Boeun (O-BE) in which the N-terminal region of VP4 is substituted with the 3C and 3D cleavage sites of FMDV, and the nucleotide sequences of VP4, VP2, VP3, and VP1 are located in order, and two copies (COPY ) shows a recombinant vector of Korea strain O-type O-Boeun (O-BE) VLP containing the gene of SEQ ID NO: 25 designed to be inserted.

20 shows the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV O-Jincheon (O-JC) in which the N-terminal region of VP4 is substituted with 3C and 3D cleavage sites of FMDV, and two copies (COPY ) shows a recombinant vector of Korea strain O-type O-Jincheon (O-JC) VLP containing the gene of SEQ ID NO: 27 designed to be inserted.

21 shows the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV O-Anseong (O-AS) in which the N-terminal region of VP4 is substituted with the 3C, 3D cleavage site of FMDV, and the nucleotide sequences of VP1 are located in order, and two copies (COPY ) shows a Korea strain O-type O-Anseong (O-AS) VLP recombinant vector containing the gene of SEQ ID NO: 29 designed to be inserted.

22 shows the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV O-Gimje (O-GJ) in which the N-terminal region of VP4 is substituted with the 3C and 3D cleavage sites of FMDV, and the nucleotide sequences of VP4, VP2, VP3, and VP1 are located in order, and two copies (COPY ) shows a recombinant vector of Korea strain O-type O-Gimje (O-GJ) VLP containing the gene of SEQ ID NO: 31 designed to be inserted.

23 is designed to insert two copies (COPY) into a vector while the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV Asia1-Shamir in which the N-terminal region of VP4 is substituted with the 3C and 3D cleavage sites of FMDV are located in order. It shows the recombinant vector of Global strain Asia1-type FMDV Asia1-Shamir VLP containing the gene of SEQ ID NO: 33.

24 is designed to insert two copies (COPY) into a vector while the nucleotide sequences of VP4, VP2, VP3, and VP1 of FMDV Asia1-Mongol in which the N-terminal region of VP4 is substituted with 3C and 3D cleavage sites of FMDV are located in order. It shows the recombinant vector of global strain Asia1-type FMDV Asia1-Mongol VLP containing the gene of SEQ ID NO: 35.

25 is a result of confirming foot-and-mouth disease virus-like particle protein expressed in Escherichia coli using Western blotting.

26 is a confirmation of FMDV VLPs expressed in E. coli using a simple FMDV diagnostic kit (VDRG ^® FMDV 3Diff/PAN Ag Rapid Kit, MEDIAN DIAGNOSTICS).

Figure 27 shows the standard calibration curve of FMDV VLP.

28 shows purified FMDV VLP antigens confirmed by transmission electron microscopes (TEM) (A: VLP of A22-Iraq, B: VLP of O-panaisa2, C: VLP of Asia1-Shamir).

29 shows that after inoculating 7-8 week old wild-type C57BL/6 mice with the vaccine prepared as shown in Table 7, mouse serum was isolated and PrioCHECK™ FMDV Type A, O, Asia1 Antibody ELISA Kit (Thermoscientific) or FMD Type O It shows the process of ELISA test using Ab ELISA kit (BIONOTE).

30 shows A22-Iraq of Example 1-1 as Global strain A-type, O-Panasia2 of Example 2-1 as Global strain O-type, O-Taiwan97 of Example 2-3, and Example 2-2 This is the result of conducting ELISA test by isolating mouse serum after vaccination with O1manisa of . 24A is the ELISA result of type A, and FIG. 24B is the ELISA result of Type O.

31 shows A-Gimpo (A-GP) of Example 1-4 as Korea strain A-type, A-Pocheon (A-PC) of Example 1-5 and Example 2-5 as Korea strain O-type After vaccination with O-Boeun (O-BE), O-Anseong (O-AS) of Example 2-7, and O-Jincheon (O-JC) of Example 2-6, mouse serum was isolated This is the result of the ELISA test.

32 shows the result of ELISA test by isolating mouse serum after inoculation with global strain Asia1-type using Asia1-Shamir of Example 3-1 as a vaccine.

33 shows an experimental procedure for inoculating a vaccine containing the FMDV VLP antigen and confirming the body weight and survival rate of mice.

34 is a global strain A-type of A22-Iraq of Example 1-1 and a global strain O-type of O-Panasia2 (OPA2) of Example 2-1 and O1manisa of Example 2-2 were vaccinated. The body weight and survival rate of the mice were shown.

35 shows A-Gimpo (A-GP) of Example 1-4 as Korea strain A-type and O-Boeun (O-BE) of Example 2-5 as Korea strain O-type, Example 2-6 It shows the body weight and survival rate of mice after inoculation with O-Jincheon (O-JC) of .

36 shows the body weight and survival rate of mice after vaccination with Asia1-Shamir of Example 3-1 as global strain Asia1-type.

37 shows a test procedure for inoculating a vaccine containing the FMDV VLP antigen, collecting mouse blood, and measuring neutralizing antibody titer (VNT).

38 is a result of measuring the neutralizing antibody titer after vaccination with Asia1-Shamir of Example 3-1 as global strain Asia1-type.

39 shows the process of inoculating pigs with the vaccine prepared as shown in Table 8, isolating pig serum, and conducting an ELISA test.

40 is a global strain A-type vaccine of A22-Iraq of Example 1-1 and an O-type vaccine of O-Panasia2 (OPA2) of Example 2-1, and then isolating porcine serum and conducting an ELISA test is a result The left (A) shows the ELISA result of Type A, and the right (B) shows the ELISA result of Type O.

41 shows the result of ELISA test by isolating porcine serum after inoculation with Global strain Asia1-type using Asia1-Shamir of Example 3-1 as a vaccine.

Hereinafter, the present specification will be described in more detail.

A detailed description of this is as follows. Meanwhile, each description and embodiment disclosed in the present invention may also be applied to other descriptions and embodiments for each. That is, all combinations of the various elements disclosed herein fall within the scope of the present invention. In addition, it cannot be seen that the scope of the present invention is limited by the specific descriptions described below.

Expressions such as “comprising” used in this specification are understood as open-ended terms that include the possibility of including other embodiments, unless specifically stated otherwise in a phrase or sentence in which the expression is included. It should be.

The terms or words used in the description and claims of the present invention should not be construed as being limited to ordinary or dictionary meanings, and the inventors use the concept of terms appropriately in order to explain their invention in the best way. Based on the principle that it can be defined, it should be interpreted as meaning and concept consistent with the technical spirit of the present invention.

As one aspect for achieving the above object, the present invention is a poly nucleotide sequence of VP4, VP2, VP3, and VP1 in which the N-terminal region of VP4 is substituted with the 3C, 3D cleavage site of foot-and-mouth disease virus (FMDV), and the nucleotide sequences of VP1 are sequentially linked. provide nucleotides.

In the present invention, the polynucleotide is for expressing foot-and-mouth disease virus-like particles by self-assembly.

In the present invention, the term "foot-and-mouth disease virus (FMDV)" belongs to the genus Aphthovirus of the Picornaviridae family. The virus consists of 60 copies of four capsid proteins (VP1, VP2, VP3, and VP4) and a single-stranded RNA genome (about 8.5 kb), and infects ungulates, especially cattle, pigs, sheep, and goats. It is a highly contagious disease.

The four capsid proteins of FMDV are VP1, VP2, VP3, and VP4, and the proteins exposed on the capsid surface are VP1, VP2, and VP3, and VP1 is most related to the infectivity of the virus. There are many serotypes depending on the region, and there are 7 serotypes such as A, O, C, SAT1, SAT2, SAT3, and Asia1 according to the antigenic structure, and these serotypes have more than 80 serotypes.

In the present invention, the term "Virus-Like Particle (VLP)" is an antigen having a shape almost identical to that of a virus, including non-structural proteins responsible for virus replication and intracellular penetration, and genetic material It has almost the same form as the virus through the combination of structural surface (envelope) proteins that represent the antigenicity of the virus using genetic recombination technology.

The envelope of foot-and-mouth disease virus is an antigenic region that is most reliably detected by the immune system after infection in the body, and safe and effective new vaccines can be prepared using proteins forming this envelope.

VLP vaccines express one or more structural proteins of viruses through molecular biology technology, and these structural proteins have a natural self-assembly ability, so they can form spatial structures and epitopes similar to natural virus particles, There is no viral nucleic acid, and it is not only highly immunogenic but also non-infectious. In addition, since high-density viral antigens exist on the surface, viruses can be delivered to immune cells in the same way as infecting a living body, effectively inducing humoral and cellular immunity of the body's immune system, and shortening the incubation period. can make it

The polynucleotide is a polynucleotide in which the N-terminal region of VP4 is substituted with the 3C, 3D cleavage site of foot-and-mouth disease virus (FMDV), and the nucleotide sequences of VP4, VP2, VP3, and VP1 are sequentially linked, and when expressed as a protein, self-assembly It is possible to prepare foot-and-mouth disease virus-like particles by

In the present invention, the foot-and-mouth disease virus may be selected from the group consisting of O serotype, A serotype, Asia serotype, SAT serotype, and C serotype.

In addition, the foot-and-mouth disease virus A serotype is A22-Iraq, A-Bangladesh (A-Ban), A-Malaysia97 (A-May97), A-Gimpo (A-GP), A-Pocheon (A-PC), and It can be selected from the group consisting of A-Yeoncheon (A-YC).

In addition, the foot-and-mouth disease virus O serotypes are O-PanAsia2 (O-PA2), O1manisa, O-Taiwan97 (O-Twn97), O-Campos, O-Boeun (O-BE), O-Jincheon (O-JC) , O-Anseong (O-AS) and O-Gimje (O-GJ).

The foot-and-mouth disease virus Asia serotype may be Asia1-Shamir or Asia1-Mongol.

The polynucleotides are SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, and SEQ ID NO: 35.

In addition, the polynucleotide is SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, It may consist of a nucleotide sequence encoding an amino acid selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, and SEQ ID NO: 36.

The 3C may consist of the nucleotide sequence of SEQ ID NO: 1 or the nucleotide sequence encoding the amino acid of SEQ ID NO: 2. The FMDV 3C is a protease, and cleaves FMDV VP4, VP2, VP3, and VP1 proteins to enable self-assembly of FMDV VLPs.

The 3D cleavage site is a part of FMDV 3D and includes only the cleavage site. The 3D is an RNA polymerase coding region, which is an enzyme that synthesizes cRNA and viral RNA using the viral RNA genome as a template. In the present invention, only the cleavage site sequence was used in the entire 3D sequence. The 3D cleavage site may consist of the nucleotide sequence of SEQ ID NO: 3 or the nucleotide sequence encoding the amino acid of SEQ ID NO: 4.

2 shows a platform for manufacturing FMDV VLPs of the present invention.

The polynucleotide is designed so that VP4-VP2-VP3-VP1 of FMDV in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially connected, and the FMDV VP1, FMDV VP2, FMDV VP3, and FMDV VP4 is a structural protein that forms the FMDV capsid.

The platform of the present invention is a 3D cleavage site (amino acid of SEQ ID NO: 4, GLIV) instead of the nucleotide sequence (GAGQ DNA Sequence in Table 1) encoding the N-terminal region (amino acid of SEQ ID NO: 135, GAGQ) of wild-type VP4. The N-terminal region of wild-type VP4 was substituted with the nucleotide sequence of SEQ ID NO: 3 (GGGTTGATCGTT).

The N-terminal region of VP4 may have the amino acid sequence of SEQ ID NO: 135. In addition, the N-terminal region of VP4 may consist of a nucleotide sequence encoding the amino acid of SEQ ID NO: 135. SEQ ID NO: 135 is an amino acid of GAGQ, and the nucleotide sequence encoding the amino acid of SEQ ID NO: 135 is shown in the GAGQ DNA Sequence in Table 1.

The amino acid sequence of SEQ ID NO: 135 is the wild-type sequence of the N-terminal region of VP4 and is conserved for each serotype. However, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 135 is different for each serotype, as in the GAGQ DNA Sequence described in Table 1.

The sequence of VP4-VP2-VP3-VP1 of FMDV is different in O serotype, A serotype, Asia1 serotype, SAT serotype, and C serotype, and the same serotype also has a different sequence for each serosubtype.

Figure 3 shows a phylogenetic diagram of foot-and-mouth disease virus.

4 is A-type FMDV A22-Iraq, A-Bangladesh (A-Ban), A-Malaysia97 (A-May97), A-Gimpo (A-GP), A-Pocheon (A-PC), and A- Comparison of amino acid sequences encoded by polynucleotides used in the production of Yeoncheon (A-YC) VLP (amino acids 2-214: 3C, amino acids 215-218: 3D cleavage site substituted at the N-terminal region of VP4 , 219-299th amino acid: VP4, 300-517th amino acid: VP2, 518-737th amino acid: VP3, 738-948th amino acid: VP1, 127th from 3C in bold P: 3C mutation position, 93rd C in VP2 bold : VP2 transition location).

5 is O-type FMDV O-PanAsia2 (O-PA2), O1manisa, O-Taiwan97 (O-Twn97), O-Campos, O-Boeun (O-BE), O-Jincheon (O-JC), O -A comparison of the amino acid sequences encoded by the polynucleotides used to prepare Anseong (O-AS) and O-Gimje (O-GJ) VLPs (amino acids 2-214: 3C, amino acids 215-218: VP4 3D cleavage site substituted at the N-terminus, amino acids 219-299: VP4, amino acids 300-517: VP2, amino acids 518-737: VP3, amino acids 738-948: VP1, 127th bold P in 3C: 3C transition location, 93rd C in VP2 in bold: VP2 transition location).

As shown in Figures 4 to 6, 3C and 3D were prepared identically without differing sequences for each FMDV serotype, and the amino acid sequence of VP4-VP2-VP3-VP1 was the same type of A serotype, O serotype or Even between Asia1 serotypes, it differs depending on the serotype.

The nucleotide sequence of SEQ ID NO: 1 is designed so that the nucleotide sequence CTG at positions 379-381 in 3C of wild-type FMDV is transformed into CCG, and the amino acid sequence of 3C encoded by SEQ ID NO: 1 also has L (leucine) at position 127 It is designed to be transformed into P (proline). The modification of 3C inhibits degradation of host factors when the polynucleotide is introduced into host cells, and maintains FMDV P1 (VP4-VP2-VP3-VP1) cleavage activity.

SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27 VP2 included in the nucleotide sequences of SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, and SEQ ID NO: 35 was designed so that the nucleotide sequences at positions 277-279 are modified as shown in Table 2, respectively, based on the nucleotide sequence of wild-type VP2. In addition, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, VP2 included in the amino acid sequences of SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, and SEQ ID NO: 36 is histidine (H), glutamine (Q), and serine (S) located at positions 93, respectively, based on the amino acid sequence of wild-type VP2. , which is designed to transform glycine (G) into cysteine (C).

As described above, through the modification of the VP2 sequence, a stable structure of the FMDV VLP was formed.

Among the polynucleotides, SEQ ID NO: 5 is a nucleotide sequence for preparing Global strain A-type FMDV A22-Iraq VLP, and is encoded by SEQ ID NO: 6 by SEQ ID NO: 5.

Among the polynucleotides, SEQ ID NO: 7 is a nucleotide sequence for preparing Global strain A-type FMDV A-Bangladesh (A-Ban) VLP, and is encoded with amino acids of SEQ ID NO: 8 by SEQ ID NO: 7.

Among the polynucleotides, SEQ ID NO: 9 is a nucleotide sequence for preparing Global strain A-type FMDV A-Malaysia97 (A-May97) VLP, and is encoded with amino acids of SEQ ID NO: 10 by SEQ ID NO: 9.

Among the polynucleotides, SEQ ID NO: 11 is a nucleotide sequence for preparing Korea strain A-type FMDV A-Gimpo (A-GP) VLP, and is encoded with amino acids of SEQ ID NO: 12 by SEQ ID NO: 11.

Among the polynucleotides, SEQ ID NO: 13 is a nucleotide sequence for preparing Korea strain A-type FMDV A-Pocheon (A-PC) VLP, and is encoded with amino acids of SEQ ID NO: 14 by SEQ ID NO: 13.

Among the polynucleotides, SEQ ID NO: 15 is a nucleotide sequence for preparing Korea strain A-type FMDV A-Yeoncheon (A-YC) VLP, and is encoded by SEQ ID NO: 15 with amino acids of SEQ ID NO: 16.

Among the polynucleotides, SEQ ID NO: 17 is a nucleotide sequence for preparing Global strain O-type FMDV O-PanAsia2 (O-PA2) VLP, and is encoded with amino acids of SEQ ID NO: 18 by SEQ ID NO: 17.

Among the polynucleotides, SEQ ID NO: 19 is a nucleotide sequence for preparing Global strain O-type FMDV O1manisa VLP, and is encoded with amino acids of SEQ ID NO: 20 by SEQ ID NO: 19.

Among the polynucleotides, SEQ ID NO: 21 is a nucleotide sequence for preparing Global strain O-type FMDV O-Taiwan97 (O-Twn97) VLP, and is encoded by SEQ ID NO: 21 with amino acids of SEQ ID NO: 22.

Among the polynucleotides, SEQ ID NO: 23 is a nucleotide sequence for preparing Global strain O-type FMDV O-Campos VLP, and is encoded with amino acids of SEQ ID NO: 24 by SEQ ID NO: 23.

Among the polynucleotides, SEQ ID NO: 25 is a nucleotide sequence for preparing Korea strain O-type FMDV O-Boeun (O-BE) VLP, and is encoded by SEQ ID NO: 25 with amino acids of SEQ ID NO: 26.

Among the polynucleotides, SEQ ID NO: 27 is a nucleotide sequence for preparing Korea strain O-type FMDV O-Jincheon (O-JC) VLP, and is encoded by SEQ ID NO: 27 with amino acids of SEQ ID NO: 28.

Among the polynucleotides, SEQ ID NO: 29 is a nucleotide sequence for preparing Korea strain O-type FMDV O-Anseong (O-AS) VLP, and is encoded with amino acids of SEQ ID NO: 30 by SEQ ID NO: 29.

Among the polynucleotides, SEQ ID NO: 31 is a nucleotide sequence for preparing Korea strain O-type FMDV O-Gimje (O-GJ) VLP, and is encoded by SEQ ID NO: 31 with amino acids of SEQ ID NO: 32.

Among the polynucleotides, SEQ ID NO: 33 is a nucleotide sequence for preparing Global strain Asia1-type FMDV Asia1-Shamir VLP, and is encoded with amino acids of SEQ ID NO: 34 by SEQ ID NO: 33.

Among the polynucleotides, SEQ ID NO: 35 is a nucleotide sequence for preparing Global strain Asia1-type FMDV Asia1-Mongol VLP, and is encoded with amino acids of SEQ ID NO: 36 by SEQ ID NO: 35.

The polynucleotide does not contain the 2A sequence previously known as essential for VLP formation, but instead places 3C at the front of the polypeptide forming the FMDV VLP and 3D cleavage site (GLIV, SEQ ID NO: 4) is placed at the N-terminus of VP4. 3C and 3D shared cleavage sites (PHHE-GLIV) exist, and 4 amino acids of the N-terminal GAGQ of VP4 are substituted with 4 GLIV of the 3D cleavage site, respectively VP1, VP2, VP3, VLP formation is possible without insertion or deletion of new amino acids in the VP4 subunit and without 2A.

As another aspect, the present invention provides a recombinant vector comprising the polynucleotide.

The "polynucleotide" is for expressing foot-and-mouth disease virus-like particles by self-assembly, as described above.

In the present invention, the term "vector" refers to any medium for cloning and/or transfer of a base into a host cell. A vector may be a replica that allows other DNA fragments to bind to result in replication of the linked fragments. "Replication unit" refers to any genetic unit (e.g., plasmid, phage, cosmid, chromosome, virus) that functions as a self-unit of DNA replication in vivo, that is, is capable of replicating under its own control. . The term "vector" includes viral and non-viral vehicles for introducing bases into host cells in vitro, ex vivo or in vivo.

In the present invention, the term "recombinant vector" refers to a vector prepared to express a target protein in a suitable host cell, and refers to a genetic construct containing essential regulatory elements operably linked to express a gene insert.

The recombinant vector of the present invention includes SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 23 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, and SEQ ID NO: 35 may include one or more polynucleotides selected from the group consisting of, and the recombinant vector is shown in FIG. As described above, two copies of the polynucleotide may be inserted.

7 shows a schematic diagram of the pET-duet vector for cloning the foot-and-mouth disease virus-like particle (FMDV VLP), and FIG. 8 shows a schematic diagram of the pACY-duet vector for cloning the foot-and-mouth disease virus-like particle ((FMDV VLP).

As the recombinant vector, a pET-duet vector and a pACY-duet vector can be used, and the polynucleotide is designed to be inserted into the MCS1 and MCS2 portions of each of the pET-duet vector and the pACY-duet vector, respectively, so that two kinds of A recombinant vector can be constructed so that 2 copies of each polynucleotide are inserted into the vector so that a total of 4 copies are inserted.

As another aspect, the present invention provides a transformant transformed with the recombinant vector.

In the present invention, the description of the term "recombinant vector" is as described above.

As used herein, the term "transformation" refers to introducing DNA into a host so that the DNA can be replicated as a chromosomal factor or by completion of chromosomal integration, and is artificially inherited by introducing external DNA into a cell. It means a phenomenon that causes change.

In the present invention, the host cell for producing the term "transformant" is preferably a host cell with high efficiency of DNA introduction and high expression efficiency of the introduced DNA, and all microorganisms including prokaryotic and eukaryotic microorganisms may be used. The host cell Escherichia ( Escherichia ) genus bacteria; Bacillus ( Bacillus ) genus bacteria; Pseudomonas ( Pseudomonas ) genus bacteria; Lactobacillus; leaven; animal cells; And it may be selected from the group consisting of insect cells, preferably, the host cell may be Escherichia coli ( E. coli ).

The transformant is for producing foot-and-mouth disease virus-like particles.

Conventional foot-and-mouth disease enveloped recombinant proteins have been commercialized to induce expression in insect cells. However, such a vaccine production system using insect cells cannot produce high-capacity VLP antigens and is expensive.

In the present invention, expression of foot-and-mouth disease virus-like particles can be induced by self-assembly in microorganisms such as Escherichia coli through modification of 3C. In addition, the transformant may be prepared by transformation with two different types of recombinant vectors.

As described above, since two copies of the polynucleotide are inserted into two different types of vectors, respectively, and a total of four copies of the recombinant vector is introduced into the host cell, the amount of FMDV VLP expression can be significantly increased.

As another aspect, the present invention comprises the steps of preparing a transformant by introducing the recombinant vector into a host cell; and culturing the transformant to induce expression of foot-and-mouth disease virus-like particles from the polynucleotide.

In the present invention, the terms "recombinant vector", "host cell", "transformant", "foot-and-mouth disease", "virus-like particle", and "polynucleotide" are explained as described above.

The method for preparing the foot-and-mouth disease virus-like particles includes introducing the recombinant vector into a host cell to prepare a transformant.

In addition, culturing the transformant to induce expression of foot-and-mouth disease virus-like particles from the polynucleotide.

The expression induction is to induce expression by culturing the transformant so as to enable self-assembly of the foot-and-mouth disease virus-like particle from the polynucleotide.

That is, the FMDV 3C-3D cleavage site is completely processed and cleaved into individual FMDV capsid proteins of VP4, VP2, VP3 and VP1 in which the N-terminal region of VP4 is substituted with the 3D cleavage site, and the cleaved capsid proteins are self-assembled Since FMDV VLPs, which are empty capsids, are formed and assembled in a form similar to foot-and-mouth disease virus, it is possible to manufacture FMDV VLPs according to the present invention.

Specifically, 3C can cleave the P1 site using a unique cleavage site by the C-terminal 4 amino acids PHHE of 3C and the 4 amino acids GLIV of 3D substituted at the N-terminus of VP4. When only four amino acids (GLIV) of the 3D cleavage site are placed behind the 3C terminus, 3C and the P1 precursor are cleaved, and accordingly, VLPs can be generated by cleavage between each VP fragment of the P1 precursor by the activity of 3C, New and improved FMDV VLP formation is possible without the addition of 2A for cleavage of P1 and 3C.

In addition, in the present invention, after cleavage of 3C and P1 sites, 4 amino acids of the N-terminal GAGQ of VP4 are substituted with 4 amino acids of GLIV of the 3D cleavage site to prevent insertion or deletion of additional amino acids, resulting in 3C With cleavage of P1 and VLP4, VLPs can be formed without adding additional amino acids.

In another aspect, the present invention is a foot-and-mouth disease virus comprising, as an active ingredient, a foot-and-mouth disease virus-like particle protein self-assembled using the polynucleotide, a protein extract of the transformant, or a recombinant protein isolated from the transformant. Provides a vaccine composition of.

In the present invention, the terms "polynucleotide", "self-assembly", "transformant", "foot-and-mouth disease", and "virus-like particle" are explained as described above.

As used herein, the term "vaccine" refers to a biological agent containing an antigen that gives immunity to a living body, and refers to an immunogen or antigenic material that immunizes a living body by injecting or orally administering to a human or animal to prevent infection. .

As used herein, the term "immunogen" or "antigenic substance" refers to a group consisting of peptides, polypeptides, lactic acid bacteria expressing the polypeptide, proteins, lactic acid bacteria expressing the protein, oligonucleotides, polynucleotides, recombinant bacteria and recombinant viruses. can be chosen For example, the antigenic material may be in the form of an inactivated whole or partial cell preparation, or an antigenic molecule obtained by conventional protein purification, genetic engineering techniques, or chemical synthesis.

The content of the antigen may be 1 to 15% by weight based on the total weight of the vaccine composition.

The vaccine composition of the present invention may further include one or more adjuvants.

The term "immune enhancer" in the present invention generally refers to any substance that increases the humoral and/or cellular immune response to an antigen. Traditional vaccines consist of unprocessed preparations of killed pathogenic microorganisms, and impurities associated with cultures of pathogenic microorganisms can act as adjuvants to enhance the immune response, but homogeneous preparations of purified protein subunits as antigens for vaccination. In case of use, the immunity triggered by such an antigen is insufficient, and therefore, the addition of some foreign substances as an immune enhancer is required. By using an adjuvant, a lower dose of antigen may be required to stimulate an immune response, thereby reducing the cost of vaccine production. These immune enhancers are classified according to their raw materials (minerals, bacteria, plants) and components (emulsion suspension). Specifically, there are cholera toxin (CT), aluminum hydroxide, carbopol, mineral oil or biodegradable oil.

The vaccine composition according to the present invention is a stabilizer, emulsifier, aluminum hydroxide, aluminum phosphate, pH adjuster, surfactant, liposome, iscom adjuvant, synthetic glycopeptide, bulking agent, carboxypolymethylene, bacterial cell wall, derivative of bacterial cell wall, Bacterial vaccine, animal poxvirus protein, subviral particle adjuvant, cholera toxin, N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl)-propanediamine, monophosphoryl lipid It may further contain at least one second adjuvant selected from the group consisting of A, dimethyldioctadecyl-ammonium bromide, and mixtures thereof.

In addition, the vaccine composition of the present invention may include a veterinarily acceptable carrier. As used herein, the term "veterinarily acceptable carrier" includes any and all solvents, dispersion media, coating agents, adjuvants, stabilizers, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and the like. Carriers, excipients, and diluents that may be included in the vaccine composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, glycerin, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

In addition, the vaccine composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and sterile injection solutions according to conventional methods, respectively. When formulated, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one or more excipients such as starch, calcium carbonate, sucrose in the lecithin-like emulsifier. It can be prepared by mixing sucrose, lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium styrate and talc may also be used. Liquid formulations for oral administration may include suspensions, internal solutions, emulsions, syrups, etc., and various excipients such as wetting agents, sweeteners, aromatics, preservatives, etc. may be included in addition to water and liquid paraffin, which are commonly used simple diluents. can Formulations for parenteral administration include sterilized aqueous solutions, water-insoluble agents, suspensions, emulsions, and lyophilized preparations. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous preparations and suspensions.

In another aspect, the present invention is a foot-and-mouth disease virus comprising, as an active ingredient, a foot-and-mouth disease virus-like particle protein self-assembled using the polynucleotide, a protein extract of the transformant, or a recombinant protein isolated from the transformant. It provides a feed composition for preventing or improving infection.

As used herein, the term "prevention" refers to a composition comprising foot-and-mouth disease virus-like particle protein self-assembled using the polynucleotide of the present invention, a protein extract of the transformant, or a recombinant protein isolated from the transformant as an active ingredient. It refers to all activities that suppress or delay the foot-and-mouth disease virus infection by administration of.

As used herein, the term "improvement" refers to a composition comprising foot-and-mouth disease virus-like particle protein self-assembled using the polynucleotide of the present invention, a protein extract of the transformant, or a recombinant protein isolated from the transformant as an active ingredient. It means any action that reduces the symptoms of foot-and-mouth disease virus infection by administration of.

The feed composition of the present invention is known in the art as long as it contains as an active ingredient the foot-and-mouth disease virus-like particle protein self-assembled using the polynucleotide, the protein extract of the transformant, or the recombinant protein isolated from the transformant. It can be appropriately configured by those skilled in the art in various types of composition ratios.

In the present invention, the feed composition may include energy, amino acids, minerals, vitamins and water as essential nutrients that must be supplied from the feed for the maintenance and growth of the object, in addition to the feed additive.

Subjects to which the feed composition of the present invention can be applied are not particularly limited and can be applied in any form. For example, it is applicable to animals such as chickens, pigs, monkeys, dogs, cats, rabbits, guinea pigs, rats, mice, cows, sheep, goats and the like without limitation.

The feed is used in the sense of including all of various feeds, functional feeds, beverages, feed additives, and beverage (negative water) additives.

In addition, in the feed composition, the amount of the active ingredient may be 0.00001% by weight or more, specifically 0.1% by weight or more, and 80% by weight or less, specifically 50% by weight or less, more specifically 40% by weight or less of the total weight of the feed composition. It may be included as, but is not limited thereto.

In another aspect, the present invention is a foot-and-mouth disease virus comprising, as an active ingredient, a foot-and-mouth disease virus-like particle protein self-assembled using the polynucleotide, a protein extract of the transformant, or a recombinant protein isolated from the transformant. Provided is a composition for adding feed to prevent or improve infection.

The term "feed additive composition" of the present invention means a material that can be added to feed to improve productivity or improve health.

The composition for feed additives of the present invention can be prepared in various forms known in the art, and is preferably a foot-and-mouth disease virus-like particle protein self-assembled using the polynucleotide, a protein extract of the transformant, or the transformant. It includes the recombinant protein isolated from the body as an active ingredient.

The feed additive according to the present invention can be used individually, can be used in combination with conventionally known feed additives, and can be used sequentially or simultaneously with conventional feed additives. And it can be single or multiple administrations. It is important to administer the amount that can obtain the maximum effect with the minimum amount without side effects in consideration of all the above factors, and can be easily determined by those skilled in the art.

The composition for feed additives of the present invention is not particularly limited to individuals to which the composition for feed can be applied, and can be applied in any form. For example, it is applicable to animals such as chickens, pigs, monkeys, dogs, cats, rabbits, guinea pigs, rats, mice, cows, sheep, goats and the like without limitation.

As another aspect, the present invention provides a method for preventing or treating foot-and-mouth disease virus, comprising administering the vaccine composition, feed composition, or feed additive composition to a mammal other than a human.

In the method of the present invention, the animal is applicable to animals such as chicken, pig, monkey, dog, cat, rabbit, guinea pig, rat, mouse, cow, sheep, goat, etc. without limitation. For example, the animal is a pig or a cow.

In the present invention, the administration may be administered by any administration means known in the art. For example, the administration may be administered directly to the subject intravenously, intramuscularly, orally, transdermal, mucosal, intranasal, intratracheal, or subcutaneously. The administration may be systemic or local administration.

In the method of the present invention, the composition of the present invention may be administered in a therapeutically or prophylactically effective amount. The "therapeutically or prophylactically effective amount" can be appropriately selected by those skilled in the art in consideration of severity of symptoms, sex, age and weight of the individual. The therapeutically or prophylactically effective amount is, for example, foot-and-mouth disease virus-like particle protein self-assembled using 1 pg to 5 g of the polynucleotide per 1 kg of the administered subject, the protein extract of the transformant, or the transformant. It may be a recombinant protein isolated from

Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings so that those skilled in the art can easily carry out the present invention. However, the present invention may be embodied in many different forms and is not limited to the embodiments described herein.

<실험예 A. 유전자 클로닝에 사용된 프라이머 및 재조합 벡터 제조><Experimental Example A. Preparation of primers and recombinant vectors used for gene cloning>

A recombinant vector for preparing virus-like particles of foot-and-mouth disease virus was prepared by genetic engineering. Recombinant vectors of the same O serotype, A serotype, and Asia1 serotype were prepared. 7 shows a schematic diagram of the pET-duet vector for cloning the foot-and-mouth disease virus-like particle (FMDV VLP), and FIG. 8 shows a schematic diagram of the pACY-duet vector for cloning the foot-and-mouth disease virus-like particle ((FMDV VLP).

First, as shown in FIG. 7, PCR was performed using the primers of SEQ ID NO: 37 and SEQ ID NO: 38, and the N-terminal region of VP4 was substituted with the 3C, 3D cleavage site of FMDV. Part of the gene fragment (except for the C-terminal region) was obtained. The PCR was performed using the gene obtained from the A22-iraq virus as a template.

And, while VP4, VP2, VP3, and VP1, in which the N-terminal region of VP4 is substituted with the 3C and 3D cleavage sites, are located in order, using forward and reverse primers of SEQ ID NOs: 39 to 70 so that they can be inserted into the pET28a vector PCR was performed, and gene fragments including the entire VP4 (including the C-terminal region), VP2, VP3, and VP1 except for a portion of the gene fragment of the VP4 were obtained. To proceed with PCR, genes obtained from foot-and-mouth disease virus for each type were used as templates.

Specifically, foot-and-mouth disease virus A serotypes are A22-Iraq, A-Bangladesh (A-Ban), A-Malaysia97 (A-May97), A-Gimpo (A-GP), A-Pocheon (A-PC), and The gene (template) obtained from the A-Yeoncheon (A-YC) virus was used as a sample, and the foot-and-mouth disease virus O serotypes were O-PanAsia2 (O-PA2), O1manisa, O-Taiwan97 (O-Twn97), and O-Campos. , O-Boeun (O-BE), O-Jincheon (O-JC), O-Anseong (O-AS), and O-Gimje (O-GJ) genes (templates) obtained from viruses were used as samples, and foot-and-mouth disease The Asia1 serotype of the virus was subjected to PCR using a template gene obtained from the Asia1-Shamir or Asia1-Mongol virus as a sample.

Part of the gene fragment of VP4 in which the N-terminal region of VP4 was substituted with the 3C-3D cut site obtained through the above two rounds of PCR (excluding the C-terminal region), and the entire VP4 except for some of the gene fragment of the VP4 (C-terminal region) The pET28a recombinant vector was prepared by ligating the gene fragment including the terminal region)-VP2-VP3-VP1 to the pET28a vector.

Next, inserting two copies of the VP4, VP2, VP3, and VP1 genes in which the N-terminal region of VP4 is substituted with the 3C, 3D cleavage site of the FMDV into MCS1 and MCS2 of the pET-duet vector To this end, PCR was performed using the pET28a-FMDV-VLP recombinant vector as a template and using forward and reverse primers of SEQ ID NOs: 71 to 134. In the pET-duet vector, the nucleotide sequences of VP4, VP2, VP3, and VP1 in which the N-terminal region of VP4 is substituted with the 3C and 3D cleavage sites of FMDV are located in order, and the two copies of the gene are located in the NcoI and EcoRI sites of MCS1, MCS2 It was designed to be inserted into the NdeI and EcoRV parts of

In addition, in the same manner as above, the pACY-duet vector was prepared by inserting two copies of the VP4, VP2, VP3, and VP1 genes in which the N-terminal region of VP4 was substituted with the 3C and 3D cleavage sites of FMDV into the pET28a vector. Accordingly, a recombinant vector was prepared such that two copies of each polynucleotide were inserted into one vector, and a total of four copies were inserted into two vectors (pET-duet, pACY-duet).

실시예 1. A-type 구제역 바이러스 유사입자(FMDV VLP) 유전자 클로닝Example 1. A-type foot-and-mouth disease virus-like particle (FMDV VLP) gene cloning

1-1. Preparation of recombinant vector of global strain A-type FMDV A22-Iraq VLP

Virus-like particles of Global strain A-type foot-and-mouth disease virus were prepared using a protein expression system using a genetic engineering method. As in Experimental Example A, PCR was performed so that the VP4, VP2, VP3, and VP1 genes of FMDV A22-Iraq in which the N-terminal region of VP4 was substituted with the 3C and 3D cleavage sites of FMDV were located in order, and the sequence number Gene fragments of 5 were obtained.

As shown in FIG. 2, the gene fragment of SEQ ID NO: 5 is designed so that VP4-VP2-VP3-VP1 of FMDV A22-Iraq in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially linked. VP2 included in SEQ ID NO: 5 is designed so that the base sequence CAC at positions 277-279 is transformed into TGT based on the base sequence of wild-type VP2 of Global strain A-type FMDV A22-Iraq, and the amino acid sequence of SEQ ID NO: 6 In the sequence, based on the wild-type VP2 amino acid sequence of Global strain A-type FMDV A22-Iraq, histidine (H) located at position 93 was designed to be modified to cysteine (C).

In addition, 3C of FMDV included in SEQ ID NO: 5 has the nucleotide sequence of SEQ ID NO: 1, and the 3D cleavage site has the nucleotide sequence of SEQ ID NO: 3. The nucleotide sequence of SEQ ID NO: 1 is designed so that the nucleotide sequence CTG at positions 379-381 in 3C of wild-type FMDV is transformed into CCG, and the amino acid sequence of 3C encoded by SEQ ID NO: 1 also has L (leucine) at position 127 It is designed to be transformed into P (proline).

To prepare the VLP of the FMDV A22-Iraq, the gene fragment of SEQ ID NO: 5 was ligated to the NcoI and EcoRI parts of MCS1 and the NdeI and EcoRV parts of MCS2 of pET-duet vector and pACY-duet vector, respectively. A recombinant vector was prepared as in A. Therefore, gene recombination was performed so that 2 copies (COPY) of the gene fragment were inserted per vector so that a total of 4 copies were inserted into the two vectors.

1-2. Global strain A-type FMDV A-Bangladesh (A-Ban) VLP recombinant vector production

Example 1, except that the gene fragment of SEQ ID NO: 7 was obtained by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV A-Bangladesh (A-Ban) instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq. A recombinant vector was prepared in the same manner as in -1.

The gene fragment of SEQ ID NO: 7 is designed so that VP4-VP2-VP3-VP1 of FMDV A-Bangladesh (A-Ban) in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially linked, VP2 included in SEQ ID NO: 7 is designed so that the base sequence CAT at positions 277-279 is transformed into TGC based on the base sequence of wild-type VP2 of Global strain A-type FMDV A-Bangladesh (A-Ban), SEQ ID NO: 8 In the amino acid sequence of Global strain A-type FMDV, based on the wild-type VP2 amino acid sequence of A-Bangladesh (A-Ban), histidine (H) located at position 93 was designed to be modified to cysteine (C).

1-3. Preparation of global strain A-type FMDV A-Malaysia97 (A-May97) VLP recombinant vector

Example 1, except that the gene fragment of SEQ ID NO: 9 was obtained by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV A-Malaysia97 (A-May97) instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq. A recombinant vector was prepared in the same manner as in -1.

The gene fragment of SEQ ID NO: 9 is designed to sequentially link VP4-VP2-VP3-VP1 of FMDV A-Malaysia97 (A-May97) in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV, VP2 included in SEQ ID NO: 9 was designed so that the base sequence CAA at positions 277-279 is transformed into TGT based on the base sequence of wild-type VP2 of Global strain A-type FMDV A-Malaysia97 (A-May97), SEQ ID NO: 10 In the amino acid sequence of Global strain A-type FMDV A-Malaysia97 (A-May97), based on the wild-type VP2 amino acid sequence, glutamine (Q) located at position 93 was designed to be modified to cysteine (C).

1-4. Preparation of Korea strain A-type FMDV A-Gimpo (A-GP) VLP recombinant vector

Example 1 except that the gene fragment of SEQ ID NO: 11 was obtained by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV A-Gimpo (A-GP) instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq. A recombinant vector was prepared in the same manner as in -1.

The gene fragment of SEQ ID NO: 11 is designed to sequentially link VP4-VP2-VP3-VP1 of FMDV A-Gimpo (A-GP) in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV, VP2 included in SEQ ID NO: 11 was designed so that the nucleotide sequence CAG at positions 277-279 is transformed into TGT based on the nucleotide sequence of wild-type VP2 of Korea strain A-type FMDV A-Gimpo (A-GP), and SEQ ID NO: 12 In the amino acid sequence of Korea strain A-type FMDV A-Gimpo (A-GP), based on the wild-type VP2 amino acid sequence, glutamine (Q) located at position 93 was designed to be modified to cysteine (C).

1-5. Construction of Korea strain A-type FMDV A-Pocheon (A-PC) VLP recombinant vector

Example 1, except that the gene fragment of SEQ ID NO: 13 was obtained by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV A-Pocheon (A-PC) instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq. A recombinant vector was prepared in the same manner as in -1.

The gene fragment of SEQ ID NO: 13 is designed so that VP4-VP2-VP3-VP1 of FMDV A-Pocheon (A-PC) in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially linked, VP2 included in SEQ ID NO: 13 was designed so that the nucleotide sequence CAG at positions 277-279 was transformed into TGT based on the nucleotide sequence of wild-type VP2 of Korea strain A-type FMDV A-Pocheon (A-PC), and SEQ ID NO: 14 In the amino acid sequence of Korea strain A-type FMDV A-Pocheon (A-PC), glutamine (Q) located at position 93 based on the wild-type VP2 amino acid sequence was designed to be modified to cysteine (C).

1-6. Construction of Korea strain A-type FMDV A-Yeoncheon (A-YC) VLP recombinant vector

Example 1, except that the gene fragment of SEQ ID NO: 15 was obtained by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV A-Yeoncheon (A-YC) instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq. A recombinant vector was prepared in the same manner as in -1.

The gene fragment of SEQ ID NO: 15 is designed so that VP4-VP2-VP3-VP1 of FMDV A-Yeoncheon (A-YC) in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially linked, VP2 included in SEQ ID NO: 15 was designed so that the nucleotide sequence CAG at positions 277-279 was transformed into TGT based on the nucleotide sequence of wild-type VP2 of Korea strain A-type FMDV A-Yeoncheon (A-YC), and SEQ ID NO: 16 In the amino acid sequence of Korea strain A-type FMDV A-Yeoncheon (A-YC), glutamine (Q) at position 93 based on the wild-type VP2 amino acid sequence was designed to be modified to cysteine (C).

실시예 2. O-type 구제역 바이러스 유사입자(FMDV VLP) 유전자 클로닝Example 2. O-type foot-and-mouth disease virus-like particle (FMDV VLP) gene cloning

2-1. Preparation of global strain O-type FMDV O-PanAsia2 (O-PA2) VLP recombinant vector

Example 1 except that the gene fragment of SEQ ID NO: 17 was obtained by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV O-PanAsia2 (O-PA2) instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq. A recombinant vector was prepared in the same manner as in -1.

The gene fragment of SEQ ID NO: 17 is designed so that VP4-VP2-VP3-VP1 of FMDV O-PanAsia2 (O-PA2) in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially linked, VP2 included in SEQ ID NO: 17 was designed so that the nucleotide sequence AGC at positions 277-279 is transformed into TGC based on the nucleotide sequence of wild-type VP2 of Global strain O-type FMDV O-PanAsia2 (O-PA2), SEQ ID NO: 18 In the amino acid sequence of Global strain O-type FMDV O-PanAsia2 (O-PA2), based on the wild-type VP2 amino acid sequence, serine (S) located at position 93 was designed to be modified to cysteine (C).

2-2. Construction of recombinant vector of global strain O-type FMDV O1manisa VLP

Instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq, the VP4, VP2, VP3, and VP1 genes of FMDV O1manisa were amplified to obtain the gene fragment of SEQ ID NO: 19, but the recombinant vector was identical to Example 1-1. was manufactured.

The gene fragment of SEQ ID NO: 19 is designed so that the VP4-VP2-VP3-VP1 of FMDV O1manisa in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially linked. VP2 was designed so that the nucleotide sequence AGC at positions 277-279 is transformed into TGC based on the nucleotide sequence of wild-type VP2 of global strain O-type FMDV O1manisa, and in the amino acid sequence of SEQ ID NO: 20, wild-type VP2 Based on the amino acid sequence, serine (S) at position 93 was designed to be modified to cysteine (C).

2-3. Preparation of global strain O-type FMDV O-Taiwan97 (O-Twn97) VLP recombinant vector

Example 1 except that the gene fragment of SEQ ID NO: 21 was obtained by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV O-Taiwan97 (O-Twn97) instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq. A recombinant vector was prepared in the same manner as in -1.

The gene fragment of SEQ ID NO: 21 is designed so that VP4-VP2-VP3-VP1 of FMDV O-Taiwan97 (O-Twn97) in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially linked, VP2 included in SEQ ID NO: 21 was designed so that the nucleotide sequence AGC at positions 277-279 is transformed into TGC based on the nucleotide sequence of wild-type VP2 of global strain O-type FMDV O-Taiwan97 (O-Twn97), SEQ ID NO: 22 In the amino acid sequence of Global strain O-type FMDV O-Taiwan97 (O-Twn97), based on the wild-type VP2 amino acid sequence, serine (S) located at position 93 was designed to be modified to cysteine (C).

2-4. Preparation of recombinant vector of global strain O-type FMDV O-Campos VLP

In the same manner as in Example 1-1, except that the gene fragment of SEQ ID NO: 23 was obtained by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV O-Campos instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq. A recombinant vector was prepared.

The gene fragment of SEQ ID NO: 23 is designed so that VP4-VP2-VP3-VP1 of FMDV O-Campos in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially linked. The included VP2 was designed so that the nucleotide sequence AGC at positions 277-279 is transformed into TGC based on the nucleotide sequence of the wild-type VP2 of Global strain O-type FMDV O-Campos, and the amino acid sequence of SEQ ID NO: 24 is Global strain O-type FMDV Based on the wild-type VP2 amino acid sequence of O-Campos, serine (S) at position 93 was designed to be modified to cysteine (C).

2-5. Preparation of Korea strain O-type FMDV O-Boeun (O-BE) VLP recombinant vector

Example 1 except that the gene fragment of SEQ ID NO: 25 was obtained by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV O-Boeun (O-BE) instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq. A recombinant vector was prepared in the same manner as in -1.

The gene fragment of SEQ ID NO: 25 is designed so that VP4-VP2-VP3-VP1 of FMDV O-Boeun (O-BE) in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially linked, VP2 included in SEQ ID NO: 25 was designed so that the nucleotide sequence GGC at positions 277-279 is transformed into TGC based on the nucleotide sequence of wild-type VP2 of Korea strain O-type FMDV O-Boeun (O-BE), and SEQ ID NO: 26 In the amino acid sequence of Korea strain O-type FMDV O-Boeun (O-BE), based on the wild-type VP2 amino acid sequence, glycine (G) located at position 93 was designed to be modified to cysteine (C).

2-6. Preparation of Korea strain O-type FMDV O-Jincheon (O-JC) VLP recombinant vector

Example 1, except that the gene fragment of SEQ ID NO: 27 was obtained by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV O-Jincheon (O-JC) instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq. A recombinant vector was prepared in the same manner as in -1.

The gene fragment of SEQ ID NO: 27 is designed so that VP4-VP2-VP3-VP1 of FMDV O-Jincheon (O-JC) in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially linked, VP2 included in SEQ ID NO: 27 was designed so that the nucleotide sequence AGC at positions 277-279 is transformed into TGC based on the nucleotide sequence of wild-type VP2 of Korea strain O-type FMDV O-Jincheon (O-JC). In the amino acid sequence of 28, serine (S) located at position 93 based on the amino acid sequence of wild type VP2 of Korea strain O-type FMDV Jincheon (O-JC) was designed to be modified to cysteine (C).

2-7. Preparation of Korea strain O-type FMDV O-Anseong (O-AS) VLP recombinant vector

Example 1 except that the gene fragment of SEQ ID NO: 29 was obtained by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV O-Anseong (O-AS) instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq. A recombinant vector was prepared in the same manner as in -1.

The gene fragment of SEQ ID NO: 29 is designed so that VP4-VP2-VP3-VP1 of FMDV O-Anseong (O-AS) in which the N-terminal part of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially linked, VP2 included in SEQ ID NO: 29 was designed so that the nucleotide sequence AGC at positions 277-279 is transformed into TGC based on the nucleotide sequence of wild-type VP2 of Korea strain O-type FMDV O-Anseong (O-AS), SEQ ID NO: 30 In the amino acid sequence of Korea strain O-type FMDV O-Anseong (O-AS), based on the wild-type VP2 amino acid sequence, serine (S) located at position 93 was designed to be modified to cysteine (C).

2-8. Preparation of Korea strain O-type FMDV O-Gimje (O-GJ) VLP recombinant vector

Example 1, except that the gene fragment of SEQ ID NO: 31 was obtained by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV O-Gimje (O-GJ) instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq. A recombinant vector was prepared in the same manner as in -1.

The gene fragment of SEQ ID NO: 31 is designed so that VP4-VP2-VP3-VP1 of FMDV O-Anseong (O-AS) in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially connected, VP2 included in SEQ ID NO: 31 was designed so that the nucleotide sequence AGC at positions 277-279 is transformed into TGC based on the nucleotide sequence of wild-type VP2 of Korea strain O-type FMDV O-Gimje (O-GJ), SEQ ID NO: 32 In the amino acid sequence of Korea strain O-type FMDV O-Gimje (O-GJ), based on the wild-type VP2 amino acid sequence, serine (S) located at position 93 was designed to be modified to cysteine (C).

실시예 3. Global strain Asia1-type 구제역 바이러스 유사입자(FMDV VLP) 유전자 클로닝Example 3. Global strain Asia1-type foot-and-mouth disease virus-like particle (FMDV VLP) gene cloning

3-1. Construction of recombinant vector of global strain Asia1-type FMDV Asia1-Shamir VLP

Except for obtaining the gene fragment of SEQ ID NO: 33 by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV Asia1-Shamir instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq, the same procedure as in Example 1-1 was performed. A recombinant vector was prepared.

The gene fragment of SEQ ID NO: 33 is designed so that VP4-VP2-VP3-VP1 of FMDV Asia1-Shamir in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV is sequentially linked. The included VP2 was designed so that the nucleotide sequence AGT at positions 277-279 is transformed into TGT based on the nucleotide sequence of wild-type VP2 of Asia1-type FMDV Asia1-Shamir, and the amino acid sequence of SEQ ID NO: 34 of Asia1-type FMDV Asia1-Shamir Based on the wild-type VP2 amino acid sequence, serine (S) at position 93 was designed to be modified to cysteine (C).

3-2. Construction of recombinant vector of global strain Asia1-type FMDV Asia1-Mongol VLP

Except for obtaining the gene fragment of SEQ ID NO: 35 by amplifying the VP4, VP2, VP3, and VP1 genes of FMDV Asia1-Mongol instead of the VP4-VP2-VP3-VP1 gene of FMDV A22-Iraq, the same procedure as in Example 1-1 was performed. A recombinant vector was prepared.

The gene fragment of SEQ ID NO: 35 is designed to sequentially link VP4-VP2-VP3-VP1 of FMDV Asia1-Mongol in which the N-terminal region of VP4 is substituted with the 3C-3D cleavage site of FMDV. The included VP2 was designed so that the nucleotide sequence AGC at positions 277-279 was transformed into TGC based on the nucleotide sequence of wild-type VP2 of Asia1-type FMDV Asia1-Mongol, and the amino acid sequence of SEQ ID NO: 36 of Asia1-type FMDV Asia1-Mongol Based on the wild-type VP2 amino acid sequence, serine (S) at position 93 was designed to be modified to cysteine (C).

실험예 1. FMDV VLP 재조합 단백질 발현 확인Experimental Example 1. Confirmation of FMDV VLP recombinant protein expression

After transforming E. coli BL21 (DE3) with the recombinant vectors prepared in Examples 1 to 3 for FMDV VLP protein expression, VLP protein expression was induced. Protein-expressed E. coli was disrupted by sonication after adding Tris-KCl buffer. After centrifuging the disrupted Escherichia coli, the supernatant was recovered, and foot-and-mouth disease virus-like particle protein was obtained through a purification process.

After SDS-PAGE of the recombinant proteins purified in Examples 1 to 3, western blotting was performed to confirm protein expression using specific antibodies to FMDV.

25 is a result of confirming foot-and-mouth disease virus-like particle protein expressed in Escherichia coli using Western blotting. As a result, in FIG. 25, Example 1-1 (A22-Iraq), 2-1 (O-PanAsia2 (O-PA2)), 2-2 (O1manisa), 3-1 (Asia1-Shamir), 1-5 (A-Pocheon(A-PC)), 1-4(A-Gimpo(A-GP)), 2-5(O-Boeun(O-BE)), 2-6(O-Jincheon(O-JC) )), it was confirmed that the FMDV VLP gene was expressed as a protein. In addition, it was confirmed that the FMDV VLPs of the other examples were also expressed in E. coli (not shown).

In addition, the purified recombinant VLP protein was dropped on the FMDV simple diagnostic kit, and after 10 to 15 minutes, expression of the foot-and-mouth disease virus-like particle recombinant protein was confirmed.

26 is a confirmation of FMDV VLPs expressed in E. coli using a simple FMDV diagnostic kit. The simple diagnostic kit used for this detection was VDRG ^® FMDV 3Diff/PAN Ag Rapid Kit (MEDIAN DIAGNOSTICS). As a result, the recombinant VLPs of Examples 1-1, 1-4, 1-5, 2-1, 2-2, 2-5, 2-6, 3-1, and 3-2 appeared positive in the simple diagnostic kit. , it was confirmed that the FMDV VLP, that is, the foot-and-mouth disease envelope structural protein gene was expressed as a protein. In addition, as shown in Table 5, the expression level of the FMDV VLP antigen was also high.

실험예 2. 백신 내 FMDV VLP 항원 함량 측정Experimental Example 2. Measurement of FMDV VLP antigen content in vaccine

The foot-and-mouth disease envelope forming protein (VLP) expressed and purified in Experimental Example 1 was quantified using an ELISA method. As a standard control, Asia1-type Asia1-Shamir VLP was used, and a standard calibration curve was prepared for ELISA quantification.

Figure 27 shows the standard calibration curve of FMDV VLP. As a result of checking the standard calibration curve, a reliable result was obtained with R ² of 0.996 (FIG. 27).

Table 6 shows the amount of foot-and-mouth disease VLP antigen through ELISA assay. As a result of quantifying the total protein of Asia1-type Asia1-Shamir by BCA assay, the total protein concentration was confirmed to be 4.0 mg/ml, and as a result of ELISA quantification, the content of VLP antigen in total protein was 19.0±1% It was confirmed that the degree Through this, it was found that the amount of VLP antigen relative to total protein was 0.76±0.04 mg/ml. In addition, since the total protein content of the vaccine was 1.0 mg, it was found that the amount of foot-and-mouth disease VLP antigen in the vaccine corresponded to 190±10 μg. Therefore, it can be seen that the antigen amount is significantly higher than that of the conventional foot-and-mouth disease vaccine, which has an antigen amount of 30 to 80 μg.

실험예 3. TEM을 이용한 FMDV VLP 항원 확인Experimental Example 3. Confirmation of FMDV VLP antigen using TEM

A TEM imaging test was performed to confirm the FMDV VLP antigen prepared by genetic recombination. The FMDV VLPs of Example 1-1 (A22-Iraq of A-type), Example 2-1 (O-panasia2 of O-type), and Example 3-1 (Asia1-Shamir of Asia1-type) were tested in Escherichia coli. After expressing, E. coli was disrupted and purified using ultra-filtration, PEG (Poly Ethylene Glycol) concentration, and open column to obtain a fraction.

28 confirms the purified FMDV VLP antigen by transmission electron microscopes (TEM). Western blot was performed on the obtained fraction, and the FMDV VLP antigen of the fraction identified by western blot was confirmed by TEM (FIG. 28). TEM imaging was conducted at the Chuncheon Center of the Korea Basic Science Institute. Example 1-1 (A22-Iraq of A-type), Example 2-1 (O-panasia2 of O-type), and Example 3-1 (Asia1-Shamir of Asia1-type) VLP sizes were all 25 It was confirmed that it was ~35 nm, and it was confirmed that it showed the same size as the foot-and-mouth disease virus.

실험예 4. FMDV VLP 재조합 백신에 대한 마우스의 항체 생성 기간 확인Experimental Example 4. Confirmation of antibody production period in mice for FMDV VLP recombinant vaccine

Vaccines for inoculation in mice were prepared as shown in Table 7 using the FMDV VLP antigen prepared in Examples 1 to 3. The FMDV VLP antigens used in vaccine production were Global strain A-type A22-Iraq of Example 1-1 and O-type O-Panasia2 (OPA2) of Example 2-1 and O-Taiwan97 of Example 2-3 (OTwn97) and O1manisa of Example 2-2 were used. A-Gimpo (A-GP) of Example 1-4 as Korea strain A-type, A-Pocheon (A-PC) of Example 1-5 and O- of Example 2-5 as Korea strain O-type Boeun (O-BE), O-Anseong (O-AS) of Example 2-7, and O-Jincheon (O-JC) of Example 2-6 were used. As Asia1-type, Asia1-Shamir of Example 3-1 was used.

29 shows that after inoculating 7-8 week-old wild-type C57BL/6 mice with the vaccine prepared as shown in Table 7, mouse serum was isolated and PrioCHECK ^TM FMDV Type A, O, Asia1 Antibody ELISA Kit (Thermoscientific) or FMD Type O It shows the process of ELISA test using Ab ELISA kit (BIONOTE). Mice were C57BL / 6N strains, 7-week-old females were used, and 200 μl was inoculated per mouse. Mouse inoculation and blood collection were performed as shown in FIG. 29 . The collected blood was separated from serum and subjected to ELISA test.

30 shows A22-Iraq of Example 1-1 as Global strain A-type, O-Panasia2 of Example 2-1 as Global strain O-type, O-Taiwan97 of Example 2-3, and Example 2-2 This is the result of conducting ELISA test by isolating mouse serum after vaccination with O1manisa of . 30A is the ELISA result of type A, and FIG. 30B is the ELISA result of Type O.

As a positive control, BIOAFTOGEN FMD Vaccine (Careside Co., Ltd) was used.

Antibody production to the A22-Iraq VLP antigen of Example 1-1 of A-type started 2 weeks after vaccination, and it was confirmed that the PI value was 30% or more after 4 weeks. In addition, the production of antibodies against the O-type O-Panasia2 (OPA2) and O1manisa VLP antigens of Example 2-1 also started 2 weeks after inoculation, and the PI value reached 50% or more after 4 weeks. In addition, the production of antibodies to the O-Taiwan97 (OTwn97) VLP antigen of Examples 2-3 of the O-type also started after 2 weeks, and the highest PI value was confirmed at 4 weeks.

In addition, antibody production against A-type A22-Iraq of Example 1-1 and O-type O-Panasia2 (OPA2) VLP antigen bivalent vaccine (A22/OPA2) of Example 2-1 Vaccination 2 It started after a week, and the PI value was the highest at 4 weeks, and the PI value was 28% for A-type and 43% for O-type (FIG. 30).

As a positive control, BIOAFTOGEN FMD Vaccine (Careside Co., Ltd) was used.

Antibody production against the VLP antigen of A-type A-Gimpo (A-GP) of Example 1-4 and A-Pocheon (A-PC) of Example 1-5 also started after 14 days (2 weeks), , PI value was more than 30% after 42 days. In addition, the production of antibodies to the O-Boeun (O-BE) VLP antigen of Examples 2-5 of the O-type also started after 14 days (2 weeks), and the PI value became more than 50% after 42 days. In addition, O-Anseong (O-AS) of Example 2-7 of Example 2-7, O-Jincheon (O-JC) of Example 2-6 Antibody production against VLP antigens also started after 14 days (2 weeks) It was confirmed that the PI value was 50% or more after 42 days (FIG. 31).

As a positive control, Aftopor (Asia1 mono, Beringer Ingelheim) was used.

Antibody production against the VLP antigen of Asia1-shamir of Example 3-1 of Asia1-type also started after 2 weeks, and it was confirmed that the PI value reached 50% or more after 4 weeks (FIG. 32).

실험예 5. FMDV VLP 재조합 백신에 대한 마우스의 몸무게 및 생존율 측정Experimental Example 5. Measurement of body weight and survival rate of mice for FMDV VLP recombinant vaccine

Vaccines containing Global strain and Korea strain FMDV VLP antigens were prepared as in Experimental Example 4, and mice were vaccinated therewith. Then, after inoculating the mouse with the foot-and-mouth disease virus, the weight of the mouse and survival of the mouse were checked.

As antigens used for vaccination, A22-Iraq of Example 1-1 as global strain A-type and O-Panasia2 (OPA2) of Example 2-1 as O-type and O1manisa of Example 2-2 were used as antigens. did A-Gimpo (A-GP) of Example 1-4 as Korea strain A-type, O-Boeun (O-BE) of Example 2-5 as Korea strain O-type, and O- of Example 2-6 Jincheon (O-JC) was used. Asia1-Shamir of Example 3-1 was used as global strain Asia1-type. 7-week-old mice of the C57BL/6N strain were vaccinated at 200 μl each. For challenge inoculation, A-type was challenged with A22 strain virus, O-type was challenged with O-Vet strain virus, and Asia1-type was challenged with A22 strain virus. Shamir strain virus was challenged. Then, body weight was measured and survival was confirmed.

As a result, mice after challenge inoculation against A-type A22-Iraq of Example 1-1, O-type O-Panasia2 (OPA2) of Example 2-1, and O1manisa VLP antigen of Example 2-2 showed an increase in body weight without a decrease, and it was confirmed that the survival rate was 100%. However, mice not inoculated with VPL antigen died after 1 week.

As a result, after inoculation with the A-type A-Gimpo (A-GP) VLP antigen of Examples 1-4, the weight of the mice showed an increase without a decrease, and it was confirmed that the survival rate was 85%. And O-Boeun (O-BE) of Examples 2-5 and O-Jincheon (O-JC) VLP antigens of Examples 2-6 after inoculation of the O-type showed an increase in body weight without loss of mice. It was confirmed that the survival rate was 100%. However, mice not inoculated with VPL antigen died after 1 week.

As a result, after challenge inoculation with the Asia1-type Asia1-shamir VLP antigen of Example 3-1, the weight of the mice showed an increase without a decrease, and it was confirmed that the survival rate was 100%.

실험예 6. FMDV VLP 재조합 백신에 대한 마우스의 중화항체 역가(VNT) 시험Experimental Example 6. Mouse neutralizing antibody titer (VNT) test for FMDV VLP recombinant vaccine

A vaccine containing the global strain Asia1-type FMDV VLP antigen was prepared as in Experimental Example 4, and after inoculating it into mice, a neutralizing antibody titer (VNT) test was performed on mouse serum. 7-week-old mice of the C57BL/6N strain were vaccinated in 200 µl each using the Asia1-shamir VLP antigen of Example 3-1 as Asia1-type, and the virus for measuring VNT was Asia1-type in case of Asia1-shamir strain used Then, the VNT value for the virus was measured.

38 is a result of measuring the neutralizing antibody titer after vaccination with Asia1-shamir of Example 3-1 as global strain Asia1-type. As a positive control, Aftopor (Asia1 mono, Beringer Ingelheim) was used.

As a result, the VNT measurement value for the Asia1-shamir VLP antigen of Example 3-1 of Asia1-type was confirmed to be 252 times (log 2.36). In addition, the VNT measurement result for the positive control vaccine was confirmed to be log 2.44, and the negative control was confirmed to be log 1.2 or less. Therefore, the vaccine prepared using the Asia1-shamir VLP antigen of Example 3-1 was confirmed to have a value similar to the VNT value of the vaccine used as a positive control.

실험예 7. FMDV VLP 재조합 백신에 대한 돼지의 항체 생성 기간 확인Experimental Example 7. Confirmation of Pig Antibody Production Period for FMDV VLP Recombinant Vaccine

Vaccines for inoculation in pigs were prepared as shown in Table 8 using the FMDV VLP antigen prepared in Examples 1 to 3. The FMDV VLP antigen used in vaccine production was A22-Iraq of Example 1-1 as global strain A-type and O-Panasia2 (OPA2) of Example 2-1 as global strain O-type. Asia1-Shamir of Example 3-1 was used as global strain Asia1-type.

39 shows the process of inoculating pigs with the vaccine prepared as shown in Table 8, isolating pig serum, and conducting an ELISA test. Pigs were used at 10-12 weeks of age, and 2 ml per pig was inoculated. Pig inoculation and blood collection were performed as shown in FIG. 33 . The collected blood was separated from serum and subjected to ELISA test.

40 is a global strain A-type vaccine of A22-Iraq of Example 1-1 and an O-type vaccine of O-Panasia2 (OPA2) of Example 2-1, and then isolating porcine serum and conducting an ELISA test is a result The left (A) shows the ELISA result of Type A, and the right (B) shows the ELISA result of Type O. As a positive control, BIOAFTOGEN FMD Vaccine (Careside Co., Ltd) was used.

Type A antibody generation against A22-Iraq of Example 1-1 of A-type and O-Panasia2 (OPA2) VLP antigen bivalent vaccine (O/A vaccine) of O-type Example 2-1 It started 2 weeks after vaccination, and after 6 weeks, the PI value was confirmed to be more than 50%. In addition, Type O antibodies to the A-type A22-Iraq of Example 1-1 and the O-type O-Panasia2 (OPA2) VLP antigen bivalent vaccine (O/A vaccine) of Example 2-1 Production also started 2 weeks after vaccination, and after 6 weeks, the PI value was confirmed to be more than 50%.

In addition, antibody production for the positive control vaccine started after 2 weeks, and after 6 weeks, the PI value was 50% or more, and it was confirmed that no antibody was produced for the negative control negative vaccine.

41 shows the result of ELISA test by isolating porcine serum after inoculation with Global strain Asia1-type using Asia1-shamir of Example 3-1.

As a positive control, Aftopor (Asia1 mono, Beringer Ingelheim) was used.

Antibody production to the Asia1-shamir VLP antigen of Example 3-1 of Asia1-type also started after 2 weeks, and after 6 weeks, the PI value was confirmed to be 50% or more. In addition, the antibody against the positive control vaccine The production started after 2 weeks, and after 6 weeks, the PI value was 50% or more, and it was confirmed that no antibody was produced for the negative control negative vaccine.

Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements of those skilled in the art using the basic concept of the present invention defined in the following claims are also made according to the present invention. falls within the scope of the rights of

Claims

A polynucleotide comprising sequentially linked nucleotide sequences of VP4, VP2, VP3, and VP1 in which the N-terminal region of VP4 is substituted with 3C and 3D cleavage sites of foot-and-mouth disease virus (FMDV).
According to claim 1,

The foot-and-mouth disease virus is selected from the group consisting of O serotype, A serotype, Asia serotype, SAT serotype, and C serotype, a polynucleotide.
According to claim 1,

The foot-and-mouth disease virus A serotypes are A22-Iraq, A-Bangladesh (A-Ban), A-Malaysia97 (A-May97), A-Gimpo (A-GP), A-Pocheon (A-PC), and A- A polynucleotide selected from the group consisting of Yeoncheon (A-YC).
According to claim 1,

The foot-and-mouth disease virus O serotypes are O-PanAsia2 (O-PA2), O1manisa, O-Taiwan97 (O-Twn97), O-Campos, O-Boeun (O-BE), O-Jincheon (O-JC), O A polynucleotide selected from the group consisting of -Anseong (O-AS) and O-Gimje (O-GJ).
According to claim 1,

The foot-and-mouth disease virus Asia1 serotype is Asia1-Shamir or Asia1-Mongol, the polynucleotide.
According to claim 1,

The polynucleotides are SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: A polynucleotide selected from the group consisting of the base sequences of SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, and SEQ ID NO: 35.
According to claim 1,

The polynucleotides are SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, and SEQ ID NO: 36, which consists of a base sequence encoding an amino acid selected from the group consisting of a polynucleotide.
According to claim 1,

The 3C is a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1 or the nucleotide sequence encoding the amino acid of SEQ ID NO: 2.
According to claim 1,

The 3D cleavage site consists of the nucleotide sequence of SEQ ID NO: 3 or the nucleotide sequence encoding the amino acid of SEQ ID NO: 4,

The N-terminal portion of the VP4 is composed of a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 135, a polynucleotide.
A recombinant vector comprising the polynucleotide of claim 1.
According to claim 10,

The recombinant vector is a recombinant vector into which two copies of the polynucleotide of claim 1 are inserted.
A transformant transformed with the recombinant vector of claim 10.
According to claim 12,

The transformant is a transformant transformed with two types of recombinant vectors.
According to claim 12,

Wherein the transformant is a transformed microorganism.
According to claim 12,

The transformant is for producing foot-and-mouth disease virus-like particles.
Preparing a transformant by introducing the recombinant vector of claim 10 into a host cell; and

culturing the transformant to induce expression of foot-and-mouth disease virus-like particles from the polynucleotide of claim 1;

A method for producing foot-and-mouth disease virus-like particles comprising a.
A foot-and-mouth disease virus vaccine composition comprising, as an active ingredient, the foot-and-mouth disease virus-like particle protein self-assembled using the polynucleotide of claim 1, the protein extract of the transformant of claim 12, or the recombinant protein isolated from the transformant.
For preventing or improving foot-and-mouth disease virus, comprising the foot-and-mouth disease virus-like particle protein self-assembled using the polynucleotide of claim 1, the protein extract of the transformant of claim 12, or the recombinant protein isolated from the transformant as an active ingredient feed composition.
For preventing or improving foot-and-mouth disease virus, comprising the foot-and-mouth disease virus-like particle protein self-assembled using the polynucleotide of claim 1, the protein extract of the transformant of claim 12, or the recombinant protein isolated from the transformant as an active ingredient A composition for adding feed.
A method for preventing or treating foot-and-mouth disease virus, comprising administering the composition of any one of claims 17 to 19 to a non-human mammal.